OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press11310.17650/1818-8346-2014-9-2-37-44HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИThe optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experienceОптимальные сроки проведения аутологичной трансплантации клеток предшественников гемопоэза при неблагоприятном течении лимфомы Ходжкина. Зарубежные рекомендации и отечественная практикаZhukovN. V.ЖуковН. В.
Russian Federation
zhukov.nikolay@rambler.ruUssA. L.УссА. Л.
Russian Federation
MilanovichN. F.МилановичН. Ф.
Russian Federation
PtushkinV. V.ПтушкинВ. В.
Russian Federation
AfanasievB. V.АфанасьевБ. В.
Russian Federation
MikhaylovaN. B.МихайловаН. Б.
Russian Federation
LarionovaV. B.ЛарионоваВ. Б.
Russian Federation
DeminaE. A.ДеминаЕ. А.
Russian Federation
TyurinaN. G.ТюринаН. Г.
Russian Federation
VernyukM. A.ВернюкМ. А.
Russian Federation
KaramaneshtE. E.КараманештЕ. Е.
Russian Federation
RumyantsevA. G.РумянцевА. Г.
Russian Federation
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow Pirogov Russian National Research Medical University, Ministry of Health of Russia, MoscowФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России, МоскваRepublic Center of Hematology and Bone Marrow Transplantation, Minsk, BelarusРеспубликанский центр гематологии и пересадки костного мозга, Минск, Республика БеларусьRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaНИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой ГБОУ ВПО Первый СПбГМУ им. И. П. Павлова Минздрава РоссииBlokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» РАМН, МоскваGertsen Moscow Research Oncology Institute, Ministry of Health of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П. А. Герцена» Минздрава РоссииKiev Center of Bone Marrow Transplantation, UkraineКиевский центр трансплантации костного мозга, Украина170920149237441709201417092014https://oncohematology.abvpress.ru/ongm/article/view/113

Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with relapsed and primary refractoryHodgkin's lymphoma (HL). According to current recommendations HSCT must be performed in first relapse or after registration of primary resistance disease. However, the HSCT in optimal time for all patients with HL who need it is impossible, due to insufficient capacity of national transplant centers. Analysis of the HSCT results from 369 HL patients treated in Russia and other CIS countries clinics showed that intensive long-term standard chemotherapy prior to transplantation is a poor prognostic factor regarding to mobilization efficacy, hematopoiesis recovery and late HSCT results. In this regard, to achieve best results HSCT must be performed no later than the second relapse or immediately after registrationof primary resistance disease. Treatment results in patients received a lot of chemotherapy before transplantation is worse. But they stillhave a chance for a cure and should be considered as potential candidates to HSCT if obtained sufficient graft quality and hematopoietic response to induction chemotherapy is achieved.

Hodgkin's lymphomarelapseprimary refractory diseasehigh-dose chemotherapyautologous transplantationmobilization of hematopoietic progenitor cellssurvivalmortalityлимфома Ходжкинарецидивпервично-резистентное течениевысокодозная химиотерапияаутологичная трансплантациямобилизация клеток предшественников гемопоэзавыживаемостьлетальность1. Franklin J., Diehl V. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol 2002;13(Suppl. 1):98–101.Franklin J., Diehl V. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol 2002;13(Suppl. 1):98–101.2. American Cancer Society.: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013. Доступно онлайн: http://www.cancer.org / acs /groups / content / @epidemiologysurveilance /documents / document / acspc-036845. pdf.American Cancer Society.: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013. Доступно онлайн: http://www.cancer.org / acs /groups / content / @epidemiologysurveilance /documents / document / acspc-036845. pdf.3. Linch D. C., Winfield D., Goldstone A. H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051–4.Linch D. C., Winfield D., Goldstone A. H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051–4.4. Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065–71.Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065–71.5. Sweetenham J. W., Carella A. M., Taghipour G. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: results in 175 patients reported to the EBMT. J Clin Oncol 1999;17:3101.Sweetenham J. W., Carella A. M., Taghipour G. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: results in 175 patients reported to the EBMT. J Clin Oncol 1999;17:3101.6. Lazarus H., Rowlings P., Zhang M. et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534.Lazarus H., Rowlings P., Zhang M. et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534.7. Reece D., Barnett M., Shepherd J. et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV + / – P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995;86:451.Reece D., Barnett M., Shepherd J. et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV + / – P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995;86:451.8. Longo D., Duffey P., Young R. et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210.Longo D., Duffey P., Young R. et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210.9. Bonfante V., Santoro A., Viviani S. et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528.Bonfante V., Santoro A., Viviani S. et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528.10. Hoppe R. T., Advani R. H., Ai W. Z. et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(5):589–97.Hoppe R. T., Advani R. H., Ai W. Z. et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(5):589–97.11. Eichenauer D. A., Engert A., Dreyling M.; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6: vi55–8.Eichenauer D. A., Engert A., Dreyling M.; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6: vi55–8.12. Collins G. P., Parker A. N., Pocock C. et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014;164(1):39–52.Collins G. P., Parker A. N., Pocock C. et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014;164(1):39–52.13. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.14. Passweg J. R., Baldomero H., Bregni M. et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161–7.Passweg J. R., Baldomero H., Bregni M. et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161–7.15. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. (Под ред. акад. М. И. Давыдова и д.б.н. Е. М. Аксель). Вестн РОНЦ им. Н. Н. Блохина РАМН 2011;22(3). Приложение 1.Статистика злокачественных новообразований в России и странах СНГ в 2007 г. (Под ред. акад. М. И. Давыдова и д.б.н. Е. М. Аксель). Вестн РОНЦ им. Н. Н. Блохина РАМН 2011;22(3). Приложение 1.16. Филатова Л. В., Тарасенкова А. А., Гершанович М. Л., Семиглазова Т. Ю. Первично-рефрактерные формы лимфомы Ходжкина. Вопр онкол 2012;58(5):627–38.Филатова Л. В., Тарасенкова А. А., Гершанович М. Л., Семиглазова Т. Ю. Первично-рефрактерные формы лимфомы Ходжкина. Вопр онкол 2012;58(5):627–38.17. Богатырева Т., Павлов В., Шкляев С. Рецидивы лимфомы Ходжкина: возможности продления жизни без высокодозной химиотерапии. Врач 2012;11:5–8.Богатырева Т., Павлов В., Шкляев С. Рецидивы лимфомы Ходжкина: возможности продления жизни без высокодозной химиотерапии. Врач 2012;11:5–8.